We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.
Patients are very satisfied with Mohs micrographic surgery (MMS) for melanoma in situ, according to a research letter recently published in Dermatologic Surgery.